Mattel unveils first Barbie with type 1 diabetes
The new Barbie has been designed in partnership with the global type 1 diabetes not-for-profit Breakthrough T1D.
"Introducing a Barbie doll with type 1 diabetes marks an important step in our commitment to inclusivity and representation," said Krista Berger, senior vice president of Barbie and global head of dolls.
"Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love."
Type 1 diabetes is an autoimmune condition where the body attacks and destroys the cells in the pancreas that make insulin.
It is often diagnosed in childhood, and patients have to monitor their glucose levels and take insulin every day.
The new doll wears a CGM — a small device that continuously measures a person's blood sugar — on her arm to help manage her condition.
To keep her CGM in place, she uses a pink heart-shaped medical tape along with a phone that displays an app to help track her blood sugar levels throughout the day.
She also has an insulin pump, a small, wearable medical device that allows for automated insulin dosing as needed, attached to her waist.
The doll is wearing a blue polka dot top and matching skirt inspired by global diabetes awareness symbols.
Alongside the new model, the company also launched a bespoke Lila Moss doll, complete with the CGM paraphernalia.
Moss, daughter of supermodel Kate Moss, was diagnosed with type 1 diabetes when she was 12 years old.
For several years Mattel has aimed to diversify its models, particularly those of the iconic doll Barbie, after having offered for decades - barring a few exceptions - a young, lithe blonde white woman with high heels.
Since 2016 the California company notably launched "curvy," "petite" and "tall" versions of Barbie.
In 2019, the company unveiled a line of "gender-inclusive" dolls as well as those with physical disabilities.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
4 days ago
- Express Tribune
Mattel unveils first Barbie with type 1 diabetes
Mattel has launched its first Barbie doll with type 1 diabetes in a bid to foster a greater sense of inclusion and empathy among children, a company vice-president said Tuesday. The new Barbie has been designed in partnership with the global type 1 diabetes not-for-profit Breakthrough T1D. "Introducing a Barbie doll with type 1 diabetes marks an important step in our commitment to inclusivity and representation," said Krista Berger, senior vice president of Barbie and global head of dolls. "Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love." Type 1 diabetes is an autoimmune condition where the body attacks and destroys the cells in the pancreas that make insulin. It is often diagnosed in childhood, and patients have to monitor their glucose levels and take insulin every day. The new doll wears a CGM — a small device that continuously measures a person's blood sugar — on her arm to help manage her condition. To keep her CGM in place, she uses a pink heart-shaped medical tape along with a phone that displays an app to help track her blood sugar levels throughout the day. She also has an insulin pump, a small, wearable medical device that allows for automated insulin dosing as needed, attached to her waist. The doll is wearing a blue polka dot top and matching skirt inspired by global diabetes awareness symbols. Alongside the new model, the company also launched a bespoke Lila Moss doll, complete with the CGM paraphernalia. Moss, daughter of supermodel Kate Moss, was diagnosed with type 1 diabetes when she was 12 years old. For several years Mattel has aimed to diversify its models, particularly those of the iconic doll Barbie, after having offered for decades - barring a few exceptions - a young, lithe blonde white woman with high heels. Since 2016 the California company notably launched "curvy," "petite" and "tall" versions of Barbie. In 2019, the company unveiled a line of "gender-inclusive" dolls as well as those with physical disabilities.
Express Tribune
6 days ago
- Express Tribune
Barbie launches first doll with type 1 diabetes
Mattel has released its first-ever Barbie doll with type 1 diabetes, expanding its Fashionistas line to include more medically inclusive representations. The new doll features a continuous glucose monitor (CGM) worn on her arm with a heart-shaped patch, an insulin pump attached at her waist, and a smartphone displaying a glucose-tracking app. -Mattel She also comes with a pastel bag meant to hold snacks and diabetes supplies. The doll wears a blue polka-dot dress, a nod to the universal color for diabetes awareness, and is priced at approximately $10.99. It was created in collaboration with Breakthrough T1D, a leading nonprofit focused on type 1 diabetes research and advocacy. Krista Berger, Senior Vice President at Barbie and Mattel, said the launch is meant to help children see themselves reflected in the toys they play with. She emphasized that representation in early childhood can lead to greater self-confidence and empathy. Medical professionals and advocates have praised the move. Leaders from Breakthrough T1D, including CEO Aaron Kowalski and UK ambassador Karen Addington, highlighted how this release helps normalize diabetes equipment and routines, potentially reducing stigma for children living with the condition. This doll joins a broader effort by Mattel to diversify its product line. Since 2019, the Fashionistas collection has featured dolls with physical disabilities, prosthetics, skin conditions, and a wide range of body types and backgrounds.
Business Recorder
30-05-2025
- Business Recorder
Free insulin to 250 children: Getz Pharma, NGO sign MoU
ISLAMABAD: In a bid to provide free insulin to children and young people with Type-1-Diabetes (T1D) Getz Pharma and a local non-profit organization (NGO) namely, Meethi Zindagi have signed a memorandum of understanding (MoU) to provide free insulin to 250 children across the country for the rest of their lives. The MoU signing ceremony held here on Thursday, attended by senior officials from both organisations, children with T1D, and their parents. The event featured engaging activities such as face painting and storytelling, where children bravely shared their journeys of living with diabetes. Getz Pharma is Pakistan's largest local pharmaceutical firm and the only company producing insulin locally. The MoU outlines that Getz Pharma will supply insulin on a quarterly basis, based on dose requirements provided by Meethi Zindagi. The non-profit will manage the identification of beneficiaries, ensure safe storage and distribution of the insulin, and provide quarterly reports on usage and outcomes. The participants were informed that during past 20 years over 18,000 children and young people have died due to complications of Type 1 Diabetes largely from lack of access to insulin. 'There are around 26,000 children and young people living with Type 1 Diabetes in Pakistan, but only about 8,000 receive free insulin,' said Dr Sana Ajmal, founder and executive director of Meethi Zindagi. 'With Getz Pharma's support, we are expanding our reach to 1,550 children—across more than 130 cities from Tharparkar to Dera Bugti—by including 250 more in our program,' she added. Dr Sana, herself a T1D patient, launched Meethi Zindagi in 2017 to help families like hers who struggled to afford insulin. Besides free insulin, the non-profit also provides peer support, medical consultations, and psychological help. 'Insulin is a right, not a privilege,' she emphasised. 'It should be available at the doorstep of every child who needs it.' Dr Wajiha Javed, associate director Public Health at Getz Pharma, said the partnership reflects the company's belief in both quality medicines and sustainable health advocacy. 'It is unacceptable that 18,000 children have died simply because they couldn't access insulin,' she said. 'Our commitment goes beyond supply we will also help create peer support networks, launch awareness campaigns for early diagnosis, and support nutritional programmes.' Highlighting Getz Pharma's unique position as the only local manufacturer of insulin in Pakistan, Dr Wajiha assured that the company would not let geographical barriers hinder its mission. 'This collaboration is a first step. We want to ensure that no child is denied a future simply because they can't afford a vial of insulin.' She maintained that during insulin shortages and crises, Getz Pharma ensured an uninterrupted supply by producing insulin locally and delivering it even to remote areas such as Parachinar. It supported thousands of patients and extended critical assistance to institutions like the Children's Hospital and the National Institute of Child Health when others stepped back. In addition to providing insulin, Getz Pharma is driving a broader, patient-focused effort to transform diabetes care in Pakistan. The company actively invests in research, runs public awareness campaigns, conducts community screenings, and supports early diagnosis initiatives. 'With a separate field force deployed nationwide to educate patients, caregivers, and healthcare providers, we ensure better disease management. This holistic approach reflects Getz Pharma's long-term commitment to addressing the root challenges of diabetes care, far beyond the supply of medicine alone', she added. Beyond insulin access, Getz Pharma empowers children with diabetes through education, nutrition support, and school-based programmes, helping them manage their condition and build healthier, informed futures, she added. As the event closed, there was a sense of hope in the air—a hope that with such powerful partnerships, Pakistan can move closer to a future where no child dies from a disease that is entirely manageable with timely access to insulin. Copyright Business Recorder, 2025
